Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to determine whether the combination of onartuzumab + erlotinib is superior (in terms of OS) to placebo + erlotinib after standard platinum-based chemotherapy in patients with Met diagnostic−positive NSCLC.
Critère d'inclusion
- MET DIAGNOSTIC−POSITIVE NON−SMALL CELL LUNG CANCER
- (NSCLC)